SlideShare une entreprise Scribd logo
1  sur  8
Télécharger pour lire hors ligne
BURDEN OF
HOLLOW TOOLS & APPROACHES
in
Product Development & Stability Studies
Roohi B. Obaid
Civil Service Officer/Deputy Director
At Drug Regulatory Authority of Pakistan
March 2017
Disclaimer:
It is written and judged in the best of author's professional knowledge, experience and education.
It has nothing to do with the organization or societies to which author is associated, so there is
no obligation to the author's organization or societies on the document. It represents current
thinking of the author on the subject. Within the boundary of good science, critical thinking and
comment with reference will always be respected
Narrowing the Confusions and Promoting Discussions based on Science
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 2 of 8 Roohi B. Obaid March 2017
Table of Contents
S. No Title Page No.
A Problem Statement 3
A-1 DRAP Recommendation 3
B Clarification 4
C Generic Drug Applications Assessment 4
D Stability Studies and Determination of Shelf Life 4
E Product Development 5
F Lab and Pilot Scale Batch Manufacturing 5
F-1 Batch Size 5
G Stability of Batches 6
G-1 Selection of Batches 6
G-2 Testing Frequency 6
H Conclusion 6
I Way Forward 6
J Project Designing & Regulatory Initiatives 7
K Reference 8
L Key Words 8
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 3 of 8 Roohi B. Obaid March 2017
A. Problem Statement:
Drug Regulatory Authority of Pakistan (DRAP) is the responsible and authorized organization
for the drug applications assessment to judge to judge the claim and promise of applicant for the
safety, quality and efficacy of the drug products. It also conducts inspection of manufacturing
facilities to monitor the state of control during the manufacturing process for integrity, quality
including consistency of the product units within a batch, batch after batch and time after time.
This role of authority has evolved in last decades for post-marketing evaluation to keep an eye on
quality surveillance and on detection of potential signals of unknown harms. Emerged safety
issues in recent past with some generics demand placement of generic drugs under surveillance
and vigilance for safety reasons. It is regrettable that DRAP has flexibility since decades for the
requirement of bioavailability/bioequivalence studies as well as in vitro dissolution studies, not
only in case of pre-registration requirements but also in case of renewal of market authorization.
The requisite support and inevitable attributes deserved to be respected for the conclusive
interest of patients are unfortunately kept unattended till date. Beside the flexible practice,
disregard to science and norms of regulatory science within DRAP have left the country and
patients on the mercy of manufacturers. It generates a perception that prevailing regulatory
procedures of DRAP are below the line and standards of competitive age. A simple example of
such practice is discussed here to clarify the situation. Development of a product is a lengthy
scientific process that requires sufficient knowledge management to generate data from trial
manufacturing. In this way, product is developed and demonstrates its overall required
performance and collects evidence that supports prediction of insignificant difference upon scale
up. Different environmental factors including immediate packaging, temperature, humidity and
light are studied for their impact on the quality of drug product. This helps in determining the
storage condition and shelf life of the product. Modern science has determined the principal to
select the sizes of batches and study protocol for determination of shelf life that prevails all
around the world and receives respect like all other scientific principle and theories.
A-1 DRAP Recommendation:
DRAP came up with their own idea that is contrary with the international norms and
standards of Regulatory Sciences for the size of batches in Product Development and
frequency of testing in Stability Studies.
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 4 of 8 Roohi B. Obaid March 2017
a) Batch size for Product Development and Stability Studies
2500 tablets for lab scale (represented as pilot scale in between lines)
b) Frequency of testing for stability studies
Week (01 to 26) intervals will be used to complete the number of tests at
both accelerated and real time conditions.
B. Clarification:
This practice of DRAP is not supported by any international reference and is not qualified yet to
demonstrate any meaningful support in determining the safety, efficacy and quality of drugs.
This is an abuse of math and a wrong approach for the foundation of product development and
stability studies on which future product quality and performance will be based.
C. Generic Drug Applications Assessment:
Generic product applications contain a set of dossier explaining mainly its Chemistry,
Manufacturing and Controls. This application is assessed to see the capability in the entire
manufacturing process of a particular formulation claiming equivalent Quality, Safety and
Efficacy with the innovator product. Its Material Quality, Manufacturing Process, Control
Strategies, Container Closure System, Comparative Dissolution Profile (CDP), Bioavailability
(BA), Bioequivalence (BE) studies etc. are the fundamental target of the Regulatory Agency to
gain reasonable trust through uniform tools for examining the claims. This assessment requires
multidisciplinary approach to make the process meaningful and navigate the decision based on
the inputs of different experts of their area of expertise. Approval or rejection of any application
principally require detailed report and its summary covering every critical aspect of the product.
D. Stability Studies and Determination of Shelf Life:
Product's stability studies are one of the subjects of paramount importance. It gives support to
understand the impact of temperature, moisture, light during the product storage determining the
shelf life of the product. In the field of life saving product manufacturing nothing can be
assumed. Every formulation requires stability studies to prove its shelf life even in case of any
change in manufacturing process or material etc. that may impact on its quality attributes.
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 5 of 8 Roohi B. Obaid March 2017
E. Product Development:
A decade old but an agreed active document of International Council of Harmonization (ICH) on
Pharmaceutical Development ICHQ8 provide an opportunity to change the approaches, from
empirical data driven to systematic knowledge driven, from retrospective to perspective, from
acceptance criteria based on limited batch data to acceptance criteria based on patient needs. It
emphasis more on science and risk based approach instead of test (document quality) that help
to understand and explore variability.
To provide a product that consistently meets patient needs, it is required to be manufactured by a
process that is well understood, robust and adaptable to the variability of input materials.
F. Lab and Pilot Scale Batch Manufacturing:
The lab scale trial batches are manufactured to understand product quality and performance. This
evolving information is used to justify the relevance of the lab scale developed manufacturing
process with relatively larger i.e. pilot scale in terms of critical processing parameters and critical
attributes to explore and strengthen the understanding of the product performance and its
manufacturing process capacity. The same way pilot scale batches are used to see potential
behavior upon scale up of commercial batch size.
F-1 Batch Sizes:
a) For Lab Scale batch, following sizes for different dosage forms are reported in
documents of the leading regulatory agencies of the world. Here it is tried to be
narrated in simple and clear words.
• For oral solid dosage forms: NLT 25% of the pilot scale batch
• Powders/solutions/suspensions: NLT 25% of the pilot scale batch
• Parenterals: NLT 25% of the pilot scale batch (50 Litre if unit is >2 ml),
(30 Litre if unit is up to 2 ml).
• Creams/Ointments: NLT 40% of the pilot scale batch
• Transdermal Patches: NLT 60% of the pilot scale batch
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 6 of 8 Roohi B. Obaid March 2017
b) For Pilot Scale batch at least one tenth of the full production scale batch or 100,
000 units (tablets or capsules), whichever is larger.
G. Stability of Batches:
G-1 Selection of Batches:
Three primary batches (one lab scale and two pilot scale) are required to generate data
with regard to stability studies. Similarity in formulation and packaging material with the
proposed commercial batches is compulsory. Moreover, the manufacturing process of
these primary batches should simulate to the proposed commercial batches capable to
promise the same quality meeting the pre-defined and studied specifications. It would be
worthy if different batches of drug substance are used to manufacture these primary
batches.
G-2 Testing Frequency:
For long term stability studies, the stability testing is required to be performed every 3
months in first year, every 6 months in the second year and then annually for the
proposed shelf life.
For 6 month accelerated stability studies, the stability testing is required to be performed
at least on 3 time points including initial and the final time point.
H. Conclusion:
Prevailing misconception (within DRAP & industry) and cross pollination of this misconception
may not favor to Patient, Regulatory System, Safety, Efficacy and Quality of the product but has
potential to perform otherwise. Respect to science for patient interest, country reputation and
industry promotion requires to keep DRAP aligned with principle of science and agreed
scientific requirements.
I. Way Forward:
Harmonization is expanding worldwide with focus to ensure the safety, efficacy and high quality
of medicines in a resource efficient way. The International Conference on Harmonization (ICH)
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 7 of 8 Roohi B. Obaid March 2017
now transformed into International Council for Harmonization is the key player in bringing
together the Regulatory Authorities and Pharmaceutical Industry of the developed world for
discussion on technical and scientific aspects. This resulted in the development of various
guidance documents on Quality, Safety, Efficacy and Multidisciplinary issues that are respected
and followed by the developed world and even the least developing world. The transformation
from Conference to Council has made it a truly global initiative expanding beyond the previous
ICH members (USA, EU and Japan) and Observers (Heath Canada and WHO), welcoming the
regulators from around the world to be involved in ICH. Efforts have been done to reduce the
regulatory burden and benefit from the experience of regulatory counterparts but without
compromising good science through confidence building exercise via memorandum of
understanding, mutual recognition agreements, joint inspection programs etc. An International
Generic Drug Regulators Program (IGDRP) has also been started to develop collaboration and
convergence in generic drug regulatory programs to address the challenges faced by increasing
workloads, globalization and complexity of scientific issues. IGDRP was initially started as a 3
year pilot (2011-2014) and is renamed as a program in 2014. It involves several countries.
Pakistan has to respect science and walk in line with the international norms of the developed
world in order to strengthen its fragile regulatory system and practices. This will not only
improve the safety, efficacy and quality of medicines available to the citizens but will also
reduce the gulf between the prevailing standards, tools and approaches compared to the rest of
the world. It will help to pull up our system at par with the international norms and to develop a
progressive strategy for regional and global harmonization. This is the only way to bring the
dream into reality of both protecting and promoting the health of citizens and pharmaceutical
industry i.e. creating a way for access of Pakistan's pharmaceutical products in the developed
world and to gain respect in the field of pharmaceutical regulation.
J. Project Designing and Regulatory Initiatives:
A balanced approach and efficient tools may be identified and designed to move in a trustworthy,
transparent, result oriented, knowledge based manner.
Burden of Hollow Tools & Approaches in Product Development & Stability Studies
Page 8 of 8 Roohi B. Obaid March 2017
K: Reference:
 International Council on Harmonization (ICH) Guidance on Stability Testing of New
Drug Substances and Products-Q1 A(R2)
 Compiled from the knowledge gained during scientific discussions, regulatory practice
and extensive reading of materials on the subject.
 Frequently asked Questions and Answers on US-FDA website
L. Key Words:
Generic Drug, Product Development, Stability Studies, Shelf Life, Batch Size, Frequency of
Testing, Lab Scale, Pilot Scale, ICH, Harmonization, Comparative Dissolution Profile (CDP),
Bioavailability (BA), Bioequivalence (BE) studies.

Contenu connexe

Tendances

Quality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsQuality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsPharmaguideline
 
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBook
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBookThe 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBook
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBookPharma IQ
 
ICH Guidlines for stability studies
ICH Guidlines for stability studiesICH Guidlines for stability studies
ICH Guidlines for stability studiesVishnu Satpute
 
Pharmaceutical preformulation and formulation
Pharmaceutical preformulation  and formulationPharmaceutical preformulation  and formulation
Pharmaceutical preformulation and formulationSuchandra03
 
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...Obaid Ali / Roohi B. Obaid
 
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...NAMSA
 
US FDA's PAT Guidance – 10 years and now
US FDA's PAT Guidance – 10 years and nowUS FDA's PAT Guidance – 10 years and now
US FDA's PAT Guidance – 10 years and nowAjaz Hussain
 
Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...
Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...
Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...Obaid Ali / Roohi B. Obaid
 
Analysis of raw materials
Analysis of raw materialsAnalysis of raw materials
Analysis of raw materialsSkAzizuddin1
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainVivek Jain
 

Tendances (20)

Quality Assurance in Pharmaceuticals
Quality Assurance in PharmaceuticalsQuality Assurance in Pharmaceuticals
Quality Assurance in Pharmaceuticals
 
Nabl
NablNabl
Nabl
 
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBook
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBookThe 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBook
The 7 Deadly Sins of Quality Assurance and Quality Control - Pharma IQ eBook
 
Preparing an IND Application: CMC
Preparing an IND Application: CMCPreparing an IND Application: CMC
Preparing an IND Application: CMC
 
Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
ICH Guidlines for stability studies
ICH Guidlines for stability studiesICH Guidlines for stability studies
ICH Guidlines for stability studies
 
Pharmaceutical preformulation and formulation
Pharmaceutical preformulation  and formulationPharmaceutical preformulation  and formulation
Pharmaceutical preformulation and formulation
 
Sampling of pharmaceuticals
Sampling  of pharmaceuticalsSampling  of pharmaceuticals
Sampling of pharmaceuticals
 
Out of specifications
Out of specificationsOut of specifications
Out of specifications
 
Q1 d step4
Q1 d step4Q1 d step4
Q1 d step4
 
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...
Cleaning Validation in Pharmaceutical Manufacturing - A Regulatory Perspectiv...
 
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...
 
40718
4071840718
40718
 
US FDA's PAT Guidance – 10 years and now
US FDA's PAT Guidance – 10 years and nowUS FDA's PAT Guidance – 10 years and now
US FDA's PAT Guidance – 10 years and now
 
Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...
Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...
Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testin...
 
Supac
SupacSupac
Supac
 
Qbd
QbdQbd
Qbd
 
ICH Q6A & ICH Q7
ICH Q6A & ICH Q7ICH Q6A & ICH Q7
ICH Q6A & ICH Q7
 
Analysis of raw materials
Analysis of raw materialsAnalysis of raw materials
Analysis of raw materials
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek Jain
 

En vedette

Draft Guidance on Physical Attributes of Tabs & Caps
Draft Guidance on Physical Attributes of Tabs & CapsDraft Guidance on Physical Attributes of Tabs & Caps
Draft Guidance on Physical Attributes of Tabs & CapsObaid Ali / Roohi B. Obaid
 
Potential Common GMP Observations and its Establishment
Potential Common GMP Observations and its Establishment Potential Common GMP Observations and its Establishment
Potential Common GMP Observations and its Establishment Obaid Ali / Roohi B. Obaid
 
Security best practices for kubernetes deployment
Security best practices for kubernetes deploymentSecurity best practices for kubernetes deployment
Security best practices for kubernetes deploymentMichael Cherny
 
Reconhecer os tempos
Reconhecer os temposReconhecer os tempos
Reconhecer os temposAlmy Alves
 
Aparato digestivo2.odt
Aparato digestivo2.odtAparato digestivo2.odt
Aparato digestivo2.odtLeire Smil
 
TCS: Trend Based Marketing - Tomorrow's Campaigns Today
TCS: Trend Based Marketing - Tomorrow's Campaigns TodayTCS: Trend Based Marketing - Tomorrow's Campaigns Today
TCS: Trend Based Marketing - Tomorrow's Campaigns TodayRoland Frasier
 
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...Obaid Ali / Roohi B. Obaid
 
Haziness in date of manufacturing and shelf life claim
Haziness in date of manufacturing and shelf life claimHaziness in date of manufacturing and shelf life claim
Haziness in date of manufacturing and shelf life claimObaid Ali / Roohi B. Obaid
 

En vedette (20)

Social media policy whatsApp group
Social media policy whatsApp group Social media policy whatsApp group
Social media policy whatsApp group
 
Social media policy - CCK Group - Facebook Wall.
Social media policy - CCK Group - Facebook Wall.Social media policy - CCK Group - Facebook Wall.
Social media policy - CCK Group - Facebook Wall.
 
Dissolution & Alternate Analytical Method
Dissolution & Alternate Analytical MethodDissolution & Alternate Analytical Method
Dissolution & Alternate Analytical Method
 
Draft Policy on Brand Name Analysis
Draft Policy on Brand Name AnalysisDraft Policy on Brand Name Analysis
Draft Policy on Brand Name Analysis
 
Draft Guidance on Physical Attributes of Tabs & Caps
Draft Guidance on Physical Attributes of Tabs & CapsDraft Guidance on Physical Attributes of Tabs & Caps
Draft Guidance on Physical Attributes of Tabs & Caps
 
Potential Common GMP Observations and its Establishment
Potential Common GMP Observations and its Establishment Potential Common GMP Observations and its Establishment
Potential Common GMP Observations and its Establishment
 
O coelho Joaquim
O coelho JoaquimO coelho Joaquim
O coelho Joaquim
 
Security best practices for kubernetes deployment
Security best practices for kubernetes deploymentSecurity best practices for kubernetes deployment
Security best practices for kubernetes deployment
 
Claim & Reasonable Probability
Claim & Reasonable ProbabilityClaim & Reasonable Probability
Claim & Reasonable Probability
 
Drug Safety Alert 6 Acetaminophen
Drug Safety Alert 6 AcetaminophenDrug Safety Alert 6 Acetaminophen
Drug Safety Alert 6 Acetaminophen
 
Reconhecer os tempos
Reconhecer os temposReconhecer os tempos
Reconhecer os tempos
 
Aparato digestivo2.odt
Aparato digestivo2.odtAparato digestivo2.odt
Aparato digestivo2.odt
 
Drug Safety Alert 5 Ketoconazole
Drug Safety Alert 5 KetoconazoleDrug Safety Alert 5 Ketoconazole
Drug Safety Alert 5 Ketoconazole
 
TCS: Trend Based Marketing - Tomorrow's Campaigns Today
TCS: Trend Based Marketing - Tomorrow's Campaigns TodayTCS: Trend Based Marketing - Tomorrow's Campaigns Today
TCS: Trend Based Marketing - Tomorrow's Campaigns Today
 
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
 
2 OARO-Interactive Discusion-04 Feb 2017
2  OARO-Interactive Discusion-04 Feb 20172  OARO-Interactive Discusion-04 Feb 2017
2 OARO-Interactive Discusion-04 Feb 2017
 
Haziness in date of manufacturing and shelf life claim
Haziness in date of manufacturing and shelf life claimHaziness in date of manufacturing and shelf life claim
Haziness in date of manufacturing and shelf life claim
 
5 OARO-Inspector's Eye -04 Feb 2017
5  OARO-Inspector's Eye -04 Feb 20175  OARO-Inspector's Eye -04 Feb 2017
5 OARO-Inspector's Eye -04 Feb 2017
 
OARO 11 Feb 2017
OARO  11 Feb 2017OARO  11 Feb 2017
OARO 11 Feb 2017
 
5 of 5 Quality Metrics & Science by Obaid Ali
5 of 5  Quality Metrics & Science by Obaid Ali5 of 5  Quality Metrics & Science by Obaid Ali
5 of 5 Quality Metrics & Science by Obaid Ali
 

Similaire à PQRS-CCK (ICH- Q1) March 2017

Stages of scale up process mparm 1st year pharmaceutical process chemistry
Stages of scale up process mparm 1st year pharmaceutical process chemistryStages of scale up process mparm 1st year pharmaceutical process chemistry
Stages of scale up process mparm 1st year pharmaceutical process chemistryDhanashreeSarwan
 
Oral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdf
Oral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdfOral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdf
Oral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdfJenniferGuerrero53
 
Generic Drugs Application Under Regulatory Microscope
Generic Drugs Application Under Regulatory Microscope Generic Drugs Application Under Regulatory Microscope
Generic Drugs Application Under Regulatory Microscope Obaid Ali / Roohi B. Obaid
 
PharmaceuticalQuality by Design (QbD) An Introduction Process Development a...
PharmaceuticalQuality by Design (QbD)   An Introduction Process Development a...PharmaceuticalQuality by Design (QbD)   An Introduction Process Development a...
PharmaceuticalQuality by Design (QbD) An Introduction Process Development a...Bachu Sreekanth
 
ICH Pharmaceutical development guideline-Q8
ICH Pharmaceutical development guideline-Q8ICH Pharmaceutical development guideline-Q8
ICH Pharmaceutical development guideline-Q8vedanshu malviya
 
Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Atul Bhombe
 
LectureItechnology transfer6thJanuary2022 (1).pptx
LectureItechnology transfer6thJanuary2022 (1).pptxLectureItechnology transfer6thJanuary2022 (1).pptx
LectureItechnology transfer6thJanuary2022 (1).pptxSohailSheikh62
 
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"Talha Mahmood
 
DRUG STABILITY ppt.ppt
DRUG STABILITY ppt.pptDRUG STABILITY ppt.ppt
DRUG STABILITY ppt.pptrameshjanga11
 
Process development
Process developmentProcess development
Process development9160676107
 
Good manufacturing and validation
Good manufacturing and validation Good manufacturing and validation
Good manufacturing and validation IshwarJadhav4
 
Key Considerations in Stability Studies for Biopharmaceuticals
Key Considerations in Stability Studies for BiopharmaceuticalsKey Considerations in Stability Studies for Biopharmaceuticals
Key Considerations in Stability Studies for BiopharmaceuticalsSGS
 
Quality by-design in pharmaceutical development
Quality by-design in pharmaceutical developmentQuality by-design in pharmaceutical development
Quality by-design in pharmaceutical developmentritu mishra
 
Review of pharmaceutical product, packaging and ich
Review of pharmaceutical product, packaging and ichReview of pharmaceutical product, packaging and ich
Review of pharmaceutical product, packaging and ichDeepak Shukla
 

Similaire à PQRS-CCK (ICH- Q1) March 2017 (20)

Stages of scale up process mparm 1st year pharmaceutical process chemistry
Stages of scale up process mparm 1st year pharmaceutical process chemistryStages of scale up process mparm 1st year pharmaceutical process chemistry
Stages of scale up process mparm 1st year pharmaceutical process chemistry
 
Oral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdf
Oral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdfOral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdf
Oral Solid Dosage Forms Pre_Post Approval Issues (1_94) _ FDA.pdf
 
Generic Drugs Application Under Regulatory Microscope
Generic Drugs Application Under Regulatory Microscope Generic Drugs Application Under Regulatory Microscope
Generic Drugs Application Under Regulatory Microscope
 
PharmaceuticalQuality by Design (QbD) An Introduction Process Development a...
PharmaceuticalQuality by Design (QbD)   An Introduction Process Development a...PharmaceuticalQuality by Design (QbD)   An Introduction Process Development a...
PharmaceuticalQuality by Design (QbD) An Introduction Process Development a...
 
ICH Pharmaceutical development guideline-Q8
ICH Pharmaceutical development guideline-Q8ICH Pharmaceutical development guideline-Q8
ICH Pharmaceutical development guideline-Q8
 
ANDA.pptx
ANDA.pptxANDA.pptx
ANDA.pptx
 
Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)
 
LectureItechnology transfer6thJanuary2022 (1).pptx
LectureItechnology transfer6thJanuary2022 (1).pptxLectureItechnology transfer6thJanuary2022 (1).pptx
LectureItechnology transfer6thJanuary2022 (1).pptx
 
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
 
ICH Q8
ICH Q8ICH Q8
ICH Q8
 
DRUG STABILITY ppt.ppt
DRUG STABILITY ppt.pptDRUG STABILITY ppt.ppt
DRUG STABILITY ppt.ppt
 
Drug stability
Drug stability Drug stability
Drug stability
 
Q5 c step4
Q5 c step4Q5 c step4
Q5 c step4
 
Process development
Process developmentProcess development
Process development
 
WJPR 6039
WJPR 6039 WJPR 6039
WJPR 6039
 
Good manufacturing and validation
Good manufacturing and validation Good manufacturing and validation
Good manufacturing and validation
 
Key Considerations in Stability Studies for Biopharmaceuticals
Key Considerations in Stability Studies for BiopharmaceuticalsKey Considerations in Stability Studies for Biopharmaceuticals
Key Considerations in Stability Studies for Biopharmaceuticals
 
Quality by-design in pharmaceutical development
Quality by-design in pharmaceutical developmentQuality by-design in pharmaceutical development
Quality by-design in pharmaceutical development
 
Review of pharmaceutical product, packaging and ich
Review of pharmaceutical product, packaging and ichReview of pharmaceutical product, packaging and ich
Review of pharmaceutical product, packaging and ich
 
2 - Dashboard (Clarifications & Updates)
2  - Dashboard (Clarifications & Updates)2  - Dashboard (Clarifications & Updates)
2 - Dashboard (Clarifications & Updates)
 

Plus de Obaid Ali / Roohi B. Obaid

A Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological ProductsA Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological ProductsObaid Ali / Roohi B. Obaid
 
Centre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdfCentre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdfObaid Ali / Roohi B. Obaid
 
Demonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdfDemonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdfObaid Ali / Roohi B. Obaid
 
Track, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdfTrack, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdfObaid Ali / Roohi B. Obaid
 
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdfObaid Ali / Roohi B. Obaid
 
Judging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the LineJudging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the LineObaid Ali / Roohi B. Obaid
 

Plus de Obaid Ali / Roohi B. Obaid (20)

A Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological ProductsA Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological Products
 
Centre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdfCentre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdf
 
A Tragic Resistance to Learn.pdf
A Tragic Resistance to Learn.pdfA Tragic Resistance to Learn.pdf
A Tragic Resistance to Learn.pdf
 
230930.pdf
230930.pdf230930.pdf
230930.pdf
 
Demonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdfDemonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdf
 
Track, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdfTrack, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdf
 
Confidence on Generics.pdf
Confidence on Generics.pdfConfidence on Generics.pdf
Confidence on Generics.pdf
 
Neurotoxicity & Neurodegenaration.pdf
Neurotoxicity & Neurodegenaration.pdfNeurotoxicity & Neurodegenaration.pdf
Neurotoxicity & Neurodegenaration.pdf
 
Application of Data & AI in Pharma 4
Application of Data & AI in Pharma 4Application of Data & AI in Pharma 4
Application of Data & AI in Pharma 4
 
PICS-ICH
PICS-ICHPICS-ICH
PICS-ICH
 
Quality Affairs of Pharmaceuticals
Quality Affairs of PharmaceuticalsQuality Affairs of Pharmaceuticals
Quality Affairs of Pharmaceuticals
 
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
 
CQS Session - RO - 16 Oct 2022.pdf
CQS Session - RO - 16 Oct 2022.pdfCQS Session - RO - 16 Oct 2022.pdf
CQS Session - RO - 16 Oct 2022.pdf
 
GMP Session for Professional Development.pdf
GMP Session for Professional Development.pdfGMP Session for Professional Development.pdf
GMP Session for Professional Development.pdf
 
Q & A - June - Sep 2022.pdf
Q & A - June - Sep 2022.pdfQ & A - June - Sep 2022.pdf
Q & A - June - Sep 2022.pdf
 
Judging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the LineJudging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the Line
 
Maturing Drug Quality to Deliver Promise
Maturing Drug Quality to Deliver PromiseMaturing Drug Quality to Deliver Promise
Maturing Drug Quality to Deliver Promise
 
PQRS 2022 - Education
PQRS  2022 - EducationPQRS  2022 - Education
PQRS 2022 - Education
 
4 - GMP June 2022 - CQS.pdf
4 - GMP June 2022 - CQS.pdf4 - GMP June 2022 - CQS.pdf
4 - GMP June 2022 - CQS.pdf
 
3 - GMP June 2022 - CQS.pdf
3 - GMP June 2022 - CQS.pdf3 - GMP June 2022 - CQS.pdf
3 - GMP June 2022 - CQS.pdf
 

Dernier

Roadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint PresentationRoadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint Presentationgdscghrcem
 
Value Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process OptimizationValue Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process OptimizationCIToolkit
 
Performance Management Notes for MBA Students
Performance Management Notes for MBA StudentsPerformance Management Notes for MBA Students
Performance Management Notes for MBA StudentsManickam Gajapathy
 
From Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EMFrom Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EMGloria Chow
 
The Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and EffectThe Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and EffectCIToolkit
 
How the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the StudioHow the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the StudioChristopher Totten
 
Applying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous ImprovementApplying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous ImprovementCIToolkit
 
HR for Non HR_Learning and Development.
HR for Non HR_Learning  and Development.HR for Non HR_Learning  and Development.
HR for Non HR_Learning and Development.azischin
 
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...AgileNetwork
 
Analyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value MappingAnalyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value MappingCIToolkit
 
Making Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity DiagramsMaking Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity DiagramsCIToolkit
 
An Important Step Toward Process Improvement
An Important Step Toward Process ImprovementAn Important Step Toward Process Improvement
An Important Step Toward Process ImprovementCIToolkit
 
Improving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba WalksImproving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba WalksCIToolkit
 
Test_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteenTest_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteenolgaz9
 
What is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdfWhat is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdfBALASUNDARESAN M
 
Tackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna RothmanTackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna RothmanStefan Wolpers
 
Forget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outsForget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outsStephan Koning
 
Organizations in a Future with Generative AI
Organizations in a Future with Generative AIOrganizations in a Future with Generative AI
Organizations in a Future with Generative AIKye Andersson
 
A3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem SolvingA3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem SolvingCIToolkit
 

Dernier (20)

Capacity2 - Briefing and Facilitation training slides
Capacity2 - Briefing and Facilitation training slidesCapacity2 - Briefing and Facilitation training slides
Capacity2 - Briefing and Facilitation training slides
 
Roadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint PresentationRoadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint Presentation
 
Value Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process OptimizationValue Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process Optimization
 
Performance Management Notes for MBA Students
Performance Management Notes for MBA StudentsPerformance Management Notes for MBA Students
Performance Management Notes for MBA Students
 
From Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EMFrom Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EM
 
The Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and EffectThe Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and Effect
 
How the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the StudioHow the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the Studio
 
Applying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous ImprovementApplying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous Improvement
 
HR for Non HR_Learning and Development.
HR for Non HR_Learning  and Development.HR for Non HR_Learning  and Development.
HR for Non HR_Learning and Development.
 
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
 
Analyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value MappingAnalyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value Mapping
 
Making Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity DiagramsMaking Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity Diagrams
 
An Important Step Toward Process Improvement
An Important Step Toward Process ImprovementAn Important Step Toward Process Improvement
An Important Step Toward Process Improvement
 
Improving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba WalksImproving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba Walks
 
Test_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteenTest_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteen
 
What is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdfWhat is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdf
 
Tackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna RothmanTackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna Rothman
 
Forget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outsForget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outs
 
Organizations in a Future with Generative AI
Organizations in a Future with Generative AIOrganizations in a Future with Generative AI
Organizations in a Future with Generative AI
 
A3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem SolvingA3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem Solving
 

PQRS-CCK (ICH- Q1) March 2017

  • 1. BURDEN OF HOLLOW TOOLS & APPROACHES in Product Development & Stability Studies Roohi B. Obaid Civil Service Officer/Deputy Director At Drug Regulatory Authority of Pakistan March 2017 Disclaimer: It is written and judged in the best of author's professional knowledge, experience and education. It has nothing to do with the organization or societies to which author is associated, so there is no obligation to the author's organization or societies on the document. It represents current thinking of the author on the subject. Within the boundary of good science, critical thinking and comment with reference will always be respected Narrowing the Confusions and Promoting Discussions based on Science
  • 2. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 2 of 8 Roohi B. Obaid March 2017 Table of Contents S. No Title Page No. A Problem Statement 3 A-1 DRAP Recommendation 3 B Clarification 4 C Generic Drug Applications Assessment 4 D Stability Studies and Determination of Shelf Life 4 E Product Development 5 F Lab and Pilot Scale Batch Manufacturing 5 F-1 Batch Size 5 G Stability of Batches 6 G-1 Selection of Batches 6 G-2 Testing Frequency 6 H Conclusion 6 I Way Forward 6 J Project Designing & Regulatory Initiatives 7 K Reference 8 L Key Words 8
  • 3. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 3 of 8 Roohi B. Obaid March 2017 A. Problem Statement: Drug Regulatory Authority of Pakistan (DRAP) is the responsible and authorized organization for the drug applications assessment to judge to judge the claim and promise of applicant for the safety, quality and efficacy of the drug products. It also conducts inspection of manufacturing facilities to monitor the state of control during the manufacturing process for integrity, quality including consistency of the product units within a batch, batch after batch and time after time. This role of authority has evolved in last decades for post-marketing evaluation to keep an eye on quality surveillance and on detection of potential signals of unknown harms. Emerged safety issues in recent past with some generics demand placement of generic drugs under surveillance and vigilance for safety reasons. It is regrettable that DRAP has flexibility since decades for the requirement of bioavailability/bioequivalence studies as well as in vitro dissolution studies, not only in case of pre-registration requirements but also in case of renewal of market authorization. The requisite support and inevitable attributes deserved to be respected for the conclusive interest of patients are unfortunately kept unattended till date. Beside the flexible practice, disregard to science and norms of regulatory science within DRAP have left the country and patients on the mercy of manufacturers. It generates a perception that prevailing regulatory procedures of DRAP are below the line and standards of competitive age. A simple example of such practice is discussed here to clarify the situation. Development of a product is a lengthy scientific process that requires sufficient knowledge management to generate data from trial manufacturing. In this way, product is developed and demonstrates its overall required performance and collects evidence that supports prediction of insignificant difference upon scale up. Different environmental factors including immediate packaging, temperature, humidity and light are studied for their impact on the quality of drug product. This helps in determining the storage condition and shelf life of the product. Modern science has determined the principal to select the sizes of batches and study protocol for determination of shelf life that prevails all around the world and receives respect like all other scientific principle and theories. A-1 DRAP Recommendation: DRAP came up with their own idea that is contrary with the international norms and standards of Regulatory Sciences for the size of batches in Product Development and frequency of testing in Stability Studies.
  • 4. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 4 of 8 Roohi B. Obaid March 2017 a) Batch size for Product Development and Stability Studies 2500 tablets for lab scale (represented as pilot scale in between lines) b) Frequency of testing for stability studies Week (01 to 26) intervals will be used to complete the number of tests at both accelerated and real time conditions. B. Clarification: This practice of DRAP is not supported by any international reference and is not qualified yet to demonstrate any meaningful support in determining the safety, efficacy and quality of drugs. This is an abuse of math and a wrong approach for the foundation of product development and stability studies on which future product quality and performance will be based. C. Generic Drug Applications Assessment: Generic product applications contain a set of dossier explaining mainly its Chemistry, Manufacturing and Controls. This application is assessed to see the capability in the entire manufacturing process of a particular formulation claiming equivalent Quality, Safety and Efficacy with the innovator product. Its Material Quality, Manufacturing Process, Control Strategies, Container Closure System, Comparative Dissolution Profile (CDP), Bioavailability (BA), Bioequivalence (BE) studies etc. are the fundamental target of the Regulatory Agency to gain reasonable trust through uniform tools for examining the claims. This assessment requires multidisciplinary approach to make the process meaningful and navigate the decision based on the inputs of different experts of their area of expertise. Approval or rejection of any application principally require detailed report and its summary covering every critical aspect of the product. D. Stability Studies and Determination of Shelf Life: Product's stability studies are one of the subjects of paramount importance. It gives support to understand the impact of temperature, moisture, light during the product storage determining the shelf life of the product. In the field of life saving product manufacturing nothing can be assumed. Every formulation requires stability studies to prove its shelf life even in case of any change in manufacturing process or material etc. that may impact on its quality attributes.
  • 5. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 5 of 8 Roohi B. Obaid March 2017 E. Product Development: A decade old but an agreed active document of International Council of Harmonization (ICH) on Pharmaceutical Development ICHQ8 provide an opportunity to change the approaches, from empirical data driven to systematic knowledge driven, from retrospective to perspective, from acceptance criteria based on limited batch data to acceptance criteria based on patient needs. It emphasis more on science and risk based approach instead of test (document quality) that help to understand and explore variability. To provide a product that consistently meets patient needs, it is required to be manufactured by a process that is well understood, robust and adaptable to the variability of input materials. F. Lab and Pilot Scale Batch Manufacturing: The lab scale trial batches are manufactured to understand product quality and performance. This evolving information is used to justify the relevance of the lab scale developed manufacturing process with relatively larger i.e. pilot scale in terms of critical processing parameters and critical attributes to explore and strengthen the understanding of the product performance and its manufacturing process capacity. The same way pilot scale batches are used to see potential behavior upon scale up of commercial batch size. F-1 Batch Sizes: a) For Lab Scale batch, following sizes for different dosage forms are reported in documents of the leading regulatory agencies of the world. Here it is tried to be narrated in simple and clear words. • For oral solid dosage forms: NLT 25% of the pilot scale batch • Powders/solutions/suspensions: NLT 25% of the pilot scale batch • Parenterals: NLT 25% of the pilot scale batch (50 Litre if unit is >2 ml), (30 Litre if unit is up to 2 ml). • Creams/Ointments: NLT 40% of the pilot scale batch • Transdermal Patches: NLT 60% of the pilot scale batch
  • 6. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 6 of 8 Roohi B. Obaid March 2017 b) For Pilot Scale batch at least one tenth of the full production scale batch or 100, 000 units (tablets or capsules), whichever is larger. G. Stability of Batches: G-1 Selection of Batches: Three primary batches (one lab scale and two pilot scale) are required to generate data with regard to stability studies. Similarity in formulation and packaging material with the proposed commercial batches is compulsory. Moreover, the manufacturing process of these primary batches should simulate to the proposed commercial batches capable to promise the same quality meeting the pre-defined and studied specifications. It would be worthy if different batches of drug substance are used to manufacture these primary batches. G-2 Testing Frequency: For long term stability studies, the stability testing is required to be performed every 3 months in first year, every 6 months in the second year and then annually for the proposed shelf life. For 6 month accelerated stability studies, the stability testing is required to be performed at least on 3 time points including initial and the final time point. H. Conclusion: Prevailing misconception (within DRAP & industry) and cross pollination of this misconception may not favor to Patient, Regulatory System, Safety, Efficacy and Quality of the product but has potential to perform otherwise. Respect to science for patient interest, country reputation and industry promotion requires to keep DRAP aligned with principle of science and agreed scientific requirements. I. Way Forward: Harmonization is expanding worldwide with focus to ensure the safety, efficacy and high quality of medicines in a resource efficient way. The International Conference on Harmonization (ICH)
  • 7. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 7 of 8 Roohi B. Obaid March 2017 now transformed into International Council for Harmonization is the key player in bringing together the Regulatory Authorities and Pharmaceutical Industry of the developed world for discussion on technical and scientific aspects. This resulted in the development of various guidance documents on Quality, Safety, Efficacy and Multidisciplinary issues that are respected and followed by the developed world and even the least developing world. The transformation from Conference to Council has made it a truly global initiative expanding beyond the previous ICH members (USA, EU and Japan) and Observers (Heath Canada and WHO), welcoming the regulators from around the world to be involved in ICH. Efforts have been done to reduce the regulatory burden and benefit from the experience of regulatory counterparts but without compromising good science through confidence building exercise via memorandum of understanding, mutual recognition agreements, joint inspection programs etc. An International Generic Drug Regulators Program (IGDRP) has also been started to develop collaboration and convergence in generic drug regulatory programs to address the challenges faced by increasing workloads, globalization and complexity of scientific issues. IGDRP was initially started as a 3 year pilot (2011-2014) and is renamed as a program in 2014. It involves several countries. Pakistan has to respect science and walk in line with the international norms of the developed world in order to strengthen its fragile regulatory system and practices. This will not only improve the safety, efficacy and quality of medicines available to the citizens but will also reduce the gulf between the prevailing standards, tools and approaches compared to the rest of the world. It will help to pull up our system at par with the international norms and to develop a progressive strategy for regional and global harmonization. This is the only way to bring the dream into reality of both protecting and promoting the health of citizens and pharmaceutical industry i.e. creating a way for access of Pakistan's pharmaceutical products in the developed world and to gain respect in the field of pharmaceutical regulation. J. Project Designing and Regulatory Initiatives: A balanced approach and efficient tools may be identified and designed to move in a trustworthy, transparent, result oriented, knowledge based manner.
  • 8. Burden of Hollow Tools & Approaches in Product Development & Stability Studies Page 8 of 8 Roohi B. Obaid March 2017 K: Reference:  International Council on Harmonization (ICH) Guidance on Stability Testing of New Drug Substances and Products-Q1 A(R2)  Compiled from the knowledge gained during scientific discussions, regulatory practice and extensive reading of materials on the subject.  Frequently asked Questions and Answers on US-FDA website L. Key Words: Generic Drug, Product Development, Stability Studies, Shelf Life, Batch Size, Frequency of Testing, Lab Scale, Pilot Scale, ICH, Harmonization, Comparative Dissolution Profile (CDP), Bioavailability (BA), Bioequivalence (BE) studies.